losartan has been researched along with Sclerosis, Systemic in 8 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
| Excerpt | Relevance | Reference |
|---|---|---|
| "Most patients with systemic sclerosis (SSc) have Raynaud's phenomenon (RP), which is often more severe than idiopathic RP." | 2.41 | Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. ( Fenlon, D; Pope, JE; Shea, B; Thompson, AE; Welch, V, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (37.50) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jego, C | 1 |
| Michaut, V | 1 |
| Graffin, B | 1 |
| Paris, JF | 1 |
| Carli, P | 1 |
| Rajendran, PR | 1 |
| Molitor, JA | 1 |
| Caskey, FJ | 1 |
| Thacker, EJ | 1 |
| Johnston, PA | 1 |
| Barnes, JN | 1 |
| Goldsmith, DJ | 1 |
| Dziadzio, M | 1 |
| Denton, CP | 1 |
| Smith, R | 1 |
| Howell, K | 1 |
| Blann, A | 1 |
| Bowers, E | 1 |
| Black, CM | 1 |
| Hasegawa, S | 1 |
| Iesato, K | 1 |
| Tsukahara, T | 1 |
| Yamamoto, S | 1 |
| Kondou, Y | 1 |
| Ogawa, M | 1 |
| Ueda, S | 1 |
| Thompson, AE | 1 |
| Shea, B | 1 |
| Welch, V | 1 |
| Fenlon, D | 1 |
| Pope, JE | 1 |
| Bridges, MJ | 1 |
| Kelly, CA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Identification of Transient Receptor Potential (TRP) Channels as New Potential Therapeutic Targets in Primary and Secondary Raynaud's Phenomenon.[NCT03211325] | 29 participants (Actual) | Interventional | 2016-10-18 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for losartan and Sclerosis, Systemic
| Article | Year |
|---|---|
Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis.
Topics: Calcium Channel Blockers; Cross-Over Studies; Humans; Iloprost; Injections, Intravenous; Ischemia; L | 2001 |
1 trial available for losartan and Sclerosis, Systemic
| Article | Year |
|---|---|
Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial.
Topics: Adult; Aged; Female; Humans; Losartan; Male; Middle Aged; Nifedipine; Pilot Projects; Raynaud Diseas | 1999 |
6 other studies available for losartan and Sclerosis, Systemic
| Article | Year |
|---|---|
[Scleroderma renal crisis following withdrawal of therapy with losartan].
Topics: Acute Disease; Anti-Inflammatory Agents; Antihypertensive Agents; Causality; Female; Humans; Hyperte | 2003 |
Resolution of hypertensive encephalopathy and scleroderma renal crisis with an angiotensin receptor blocker.
Topics: Acute Kidney Injury; Angiotensin II Type 1 Receptor Blockers; CADASIL; Female; Humans; Hypertensive | 2005 |
Failure of losartan to control blood pressure in scleroderma renal crisis.
Topics: Acute Kidney Injury; Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Comp | 1997 |
Angiotensin receptor antagonists.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihype | 1997 |
[Successful use of angiotensin II receptor antagonist (losartan) in a patient with scleroderma renal crisis].
Topics: Acute Kidney Injury; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Humans; Hypert | 2000 |
Raynaud's phenomenon affecting the tongue of a patient with scleroderma.
Topics: Female; Humans; Losartan; Middle Aged; Raynaud Disease; Scleroderma, Systemic; Tongue Diseases; Vaso | 2002 |